BME100 s2015:Group12 12pmL1: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 84: Line 84:
*The team will question the subject on why he or she wants to end the experiment, and would try to convince them to see the experiment through completion. If however the subject is resistant, they will be discharged from the experiment, and random selection will be needed to fill the vacancy.
*The team will question the subject on why he or she wants to end the experiment, and would try to convince them to see the experiment through completion. If however the subject is resistant, they will be discharged from the experiment, and random selection will be needed to fill the vacancy.


*It is one of the team’s best interests to ensure the subject’s personal views are not infringed upon for the duration of the experiment. The team will disclose any information that the subject feels needs to be addressed before entering the laboratory environment. They have the right to opt out of the experiment at any time.
*It is one of the team’s best interests to ensure the subject’s personal views are not infringed upon for the duration of the experiment. The team will disclose any information the subject requires before entering the laboratory environment. They have the right to opt out of the experiment at any time.
   
   
*The medical history of each subject participating in the inflammotin study will be required, as the team does not want to give a potentially harmful or fatal dose of lipopolysacchiride, if the case presents itself. Careful measures will be made to account for any possible consequences during the experiment, such as faulty data analysis, malfunctioning lab equipment or loss of data.
*The medical history of each subject participating in the inflammotin study will be required, as the team does not want to give a potentially harmful or fatal dose of lipopolysacchiride, if the case presents itself. Careful measures will be made to account for any possible consequences during the experiment, such as faulty data analysis, malfunctioning lab equipment or loss of data.

Revision as of 13:59, 25 January 2015

BME 100 Spring 2015 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help


OUR TEAM

Name: Corey Soto
Name: Kyla Richardson
Name: Waseem Aljaid
Name: Syeda Rizvi
Name: William Chmielewski

LAB 1 WRITE-UP

WARNING: All material presented here is highly suspectible to change by the write-up's authors. Final draft will be complete by Tuesday, 11:59 P.M.

Independent and Dependent Variables

Independent Variable: Lipopolysacchride (LPS) would be the variable the research team changes, because according to the ELISA data analysis provided, the levels of inflammotin in the blood sample analyzed were affected by a determined amount of the drug, 10 mg. The team will be able to deduce how inflammotin levels interact with a certain dosage of LPS by manipulating this variable.

Dependent Variable: Inflammotin is the protein responsible for inflammation and is the central part of the experiment the team will conduct. This variable will fluctuate based on the dosage of LPS the research team will administrator to the test groups.

Experimental Design

Groups

  • Group 1 – 8 mg
  • Group 2 – 6 mg
  • Group 3 – 4 mg
  • Group 4 – 2 mg
  • Group 5 – 0 mg (placebo, control group)

Age

Age limit is between 60 to 70 years of age. The research team believes this is the prime demographic of elderly individuals whose personal health is adequate. These individuals are less likely to succumb to biological factors such as cell decay or organ failure, often from 71 years of age and older. Such issues may complicate the experiment.


Number of subjects per group

10 subjects for each group, totaling 5 groups.





Subject Selection

  • Random selection of 50 individuals from the general population in America, but both sexes included in the study would be best.
  • Consent of the individuals is necessary, and all information regarding the experiment will be open to disclosure at the participants' request.
  • Medical history of selected individuals required (the team does not want to potentially give a harmful or fatal dose of lipopolysacchiride, if the case presents itself).
  • Particularly interested in individuals who have active levels of inflammation (the data collected would be more relevant to the study).
  • Less keen on healthy individuals whose inflammation levels are more passive or even dormant (subjects may be placed into control group to increase data accuracy).
  • Actual process of recruitment is through more emphasis on speaking to them directly in person, telephone calls, pamphlets going through the mail and advertisements for newspapers, magazines and radio stations. Less emphasis on Internet or email advertisements (the targeted demographic is less likely to use the Internet or email).






Sources of Error and Bias

  • Subjects may desire to end the experiment prematurely
  • Personal conflicts with experimentation (religious / spiritual, distrust of medical / scientific personnel, etc.)
  • Unexpected consequences during experiment (allergic reaction, sickness sets in on one or more subjects, etc.)
  • Experiment itself is ending prematurely (budget cuts too demanding, manpower redirected elsewhere, etc.)
  • Subject selection during randomization may be accidently biased (one group being entirely one race or sex)


Possible Controls:

  • The team will question the subject on why he or she wants to end the experiment, and would try to convince them to see the experiment through completion. If however the subject is resistant, they will be discharged from the experiment, and random selection will be needed to fill the vacancy.
  • It is one of the team’s best interests to ensure the subject’s personal views are not infringed upon for the duration of the experiment. The team will disclose any information the subject requires before entering the laboratory environment. They have the right to opt out of the experiment at any time.
  • The medical history of each subject participating in the inflammotin study will be required, as the team does not want to give a potentially harmful or fatal dose of lipopolysacchiride, if the case presents itself. Careful measures will be made to account for any possible consequences during the experiment, such as faulty data analysis, malfunctioning lab equipment or loss of data.
  • Realities will set in for the laboratory from time to time. Budget cuts, redirection of manpower, or the premature termination of the experiment could jeopardize the study. However, the team will establish a time frame for the conduction of the study, such as two weeks’ worth of duration. A restrictive budget will be used, and the members of the laboratory will optimize their equipment use to its full effect. Any other particular conflicts of interest for the experiment will be addressed and concluded properly.
  • Based on the nature of randomization, the groups may be affected by bias, such as one group being entirely composed of one race or sex. The team will ensure that the groups are free of such factors as much as humanly possible, and will randomize the groups until such issues are minimal.